Fig. 1From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective studyThe PFS of everolimus-treated patients with HR-positive advanced breast cancer. A total of 120 patients received everolimus. PFS, progression-free survival. HR, hormone receptorBack to article page